据程合红介绍，去年以来，证监会先后推动发布实施一系列资本市场支持科技创新的政策措施，不断完 善支持科技创新的监管体系和市场生态，努力更好发挥资本市场支持科技创新的作用。目前，在沪深北 交易所上市公司中，战略性新兴产业上市公司数量接近2700家，市值占比超四成。 编辑：王媛媛 在支持上市公司并购重组方面，证监会将落实好新修订的《上市公司重大资产重组管理办法》，进一步 激发并购重组市场活力。鼓励科技型上市公司综合运用股份、定向可转债、现金等多种支付工具实施并 购重组，推动股份对价分期支付机制、重组简易审核程序落地。 程合红表示，中国证监会还将切实做好投资者保护、加强资本市场法律制度建设、构建更加诚信友善的 市场环境。 转自：新华财经 在培育壮大长期资本、耐心资本方面，将引导私募股权基金优化长周期考核机制，更好契合科技创新企 业发展特点。支持私募股权二级市场基金（S基金）的发展，推动基金份额转让业务试点转常规，扩大 基金向投资者实物分配股票试点，促进"募投管退"的良性循环。继续引导中长期资金入市，持续完 善"长钱长投"制度。 新华财经天津6月5日电（记者李亭）中国证监会首席律师程合红5日在2025天津五大道金融论坛 ...

6月5日，嘉诚国际今日收盘11.2元，下跌2.78%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到28.36倍，总市值57.22亿元。 从行业市盈率排名来看，公司所处的物流行业行业市盈率平均25.27倍，行业中值28.32倍，嘉诚国际排 名第33位。 股东方面，截至2025年3月31日，嘉诚国际股东户数13554户，较上次增加544户，户均持股市值35.28万 元，户均持股数量2.76万股。 广州市嘉诚国际物流股份有限公司主营业务是为制造业客户提供定制化物流解决方案及全程供应链一体 化综合物流服务。公司利用自动化物流设备和先进的物流信息管理系统，为电子商务企业特别是跨境电 商企业提供个性化的全球物流解决方案及包括干、仓、关、配在内的全链路物流服务。包括智能仓储保 管、装卸搬运、包装、运输及协同配送、流通加工以及物流信息传递等全程物流服务和个性化的物流解 决方案。当前，公司已拥有数十项物流器具及设备专利技术，已成功应用的智能系统有 TMS,WMS,RFID等。 最新一期业绩显示，2025年一季报，公司实现营业收入2.84亿元，同比-2.44%；净利润6246.91万元，同 比-4.47%，销售毛 ...

迈普医学（301033）公告，公司股票将于2025年6月6日开市起复牌。公司于6月5日召开第三届董事会第 十次会议，审议通过了发行股份及支付现金购买资产并募集配套资金暨关联交易预案等相关议案。本次 交易涉及资产的审计、评估工作尚未完成，公司将在相关工作完成后再次召开董事会审议相关事项，并 提交股东会审议。本次交易尚需取得深圳证券交易所审核同意及中国证监会注册后方可正式实施，存在 不确定性。公司将继续推进本次交易并严格履行信息披露义务。 ...

精进电动公告，股东理成赛鑫及其一致行动人拟减持不超过442.69万股，占公司总股本0.75%。股东诚 辉国际拟减持不超过295.11万股，占公司总股本0.50%。股东Citron PE拟减持不超过590.22万股，占公 司总股本1%。股东超越摩尔拟减持不超过590.22万股，占公司总股本1%。减持方式包括集中竞价或大 宗交易，减持期间为2025年6月30日至2025年9月29日。 ...

Core Viewpoint - Sanofi's application for the new drug SSGJ-613, a recombinant humanized monoclonal antibody targeting IL-1β for acute gouty arthritis, has been accepted by the National Medical Products Administration after achieving primary efficacy endpoints in Phase III clinical trials [1] Group 1 - The drug SSGJ-613 is developed independently by the company and represents a novel anti-IL-1β antibody with a completely different binding epitope compared to existing products on the market targeting the same pathway [1]

爱科科技公告，股东瑞步投资及瑞松投资因自身资金需求，计划自2025年6月27日至2025年9月26日，通 过集中竞价交易方式减持不超过82.69万股，即不超过公司总股本的1.00%。瑞步投资计划减持不超过 48.18万股，减持比例不超过0.58%；瑞松投资计划减持不超过34.52万股，减持比例不超过0.42%。 ...

Core Viewpoint - The company has successfully completed the Phase III clinical trial for its innovative anti-IL-1β humanized monoclonal antibody injection (project code "GJ-613") for the treatment of acute gouty arthritis, achieving the primary efficacy endpoints and has submitted a new drug application to the National Medical Products Administration [1] Group 1 - The drug GJ-613 is developed independently by the company and possesses its own intellectual property rights, differentiating itself from existing products targeting the same pathway, such as Canakinumab and Gevokizumab, by having completely different binding epitopes [1] - The completed Phase III clinical study demonstrated that GJ-613 effectively alleviates pain in acute gouty arthritis and prevents recurrence, achieving dual primary efficacy endpoints comparable to the positive control drug, compound betamethasone injection, and significantly outperforming it [1]

Group 1 - The meeting between the Secretary of the Provincial Party Committee Liu Ning and the Chairman of China Power Construction Group Ding Yanzhang highlights the importance of collaboration for high-quality economic development in Henan [1][2] - Liu Ning emphasized the need for a clean, low-carbon, safe, and efficient energy system, aligning with national strategies such as the Yellow River National Strategy and major infrastructure projects [1] - China Power Construction Group aims to leverage its core advantages in water, energy, urban infrastructure, and digital sectors to enhance resource investment and accelerate key project construction in Henan [2] Group 2 - The provincial government expressed commitment to support China Power Construction Group's investments in Henan by optimizing the business environment and ensuring service guarantees [1] - The meeting coincided with World Environment Day, underscoring the focus on ecological protection and sustainable development in the region [1] - China Power Construction Group's integrated advantages in investment, construction, and operation are expected to contribute significantly to Henan's modernization efforts [2]

最新一期业绩显示，2025年一季报，公司实现营业收入1.74亿元，同比-20.46%；净利润1545.37万元， 同比-39.20%，销售毛利率24.54%。 6月5日，新中港今日收盘7.74元，上涨3.20%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到22.70倍，创11天以来新低，总市值31.00亿元。 从行业市盈率排名来看，公司所处的公用事业行业市盈率平均26.27倍，行业中值27.77倍，新中港排名 第11位。 股东方面，截至2025年3月31日，新中港股东户数21303户，较上次增加793户，户均持股市值35.28万 元，户均持股数量2.76万股。 浙江新中港热电股份有限公司的主营业务是采用热电联产的方式进行热力产品、电力产品和压缩空气的 生产及供应。公司的主要产品是蒸汽、电力（热电联产）、电力（储能电力）、压缩空气、煤炭。电力 产品出售给国家电网公司供应终端电力用户。公司是浙江省首个全厂通过超低排放验收的热电厂。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11新中港22.7021.162.3931.00亿行业平均 26.2725.831.7081.64亿行业中值27. ...

Market Performance - The Guoxin Humanoid Robot Index declined by 3.88% during the week of May 26-30, underperforming the CSI 300 Index by 2.79 percentage points and the Shanghai Composite Index by 3.85 percentage points, with a year-to-date increase of 8.4% [1] - Notable declines in individual stocks include Top Group down 3.95%, Sanhua Intelligent Control down 4.58%, and Zhongding Sealing down 5.6%, while Beite Technology increased by 2.99% [1] Industry Dynamics - Elon Musk announced that the Optimus humanoid robot is expected to walk on Mars by 2027 [2] - Various companies, including Tesla and Xiaoma Zhixing, are releasing plans related to Robotaxi [2] - Honor is entering the humanoid robot sector, and a joint laboratory is being established between Zhujie Power and the Guangdong Embodied Intelligent Robot Innovation Center [2] - The establishment of the Embodied Intelligence Data Alliance and the launch of new products, such as the TrackVLA navigation model by Galaxy General, indicate advancements in the industry [2] - Several companies have completed significant financing rounds, including Digua Robotics with $100 million in Series A funding [2] Core Viewpoint - The production rhythm of Tesla's humanoid robot Optimus is becoming clearer, with ongoing developments from major players in the industry, suggesting that the humanoid robot sector may accelerate its implementation [3] - The year 2025 is anticipated to be a pivotal point for industry growth, presenting opportunities for industrial upgrades [3] Investment Recommendations - Recommended companies in the assembly segment include Top Group and Sanhua Intelligent Control [3] - In the reducer segment, Double Ring Transmission, Precision Forging Technology, and Zhongding Sealing are highlighted [3] - For the sensor segment, Lingyun shares are recommended, along with other related companies such as Silver Wheel Technology and Junsheng Electronics [3]